| Schedule of Reportable Segment and the Significant Expenses, Including Consolidated Net Income (Loss) |
The following table sets
forth information about the Company’s single reportable segment and the significant expenses reviewed by the CODM, including a
reconciliation to consolidated net income (loss):
| | |
For the Three Months Ended
June 30, | | |
For the Six Months Ended
June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Research and development expenses: | |
| | |
| | |
| | |
| |
| TARA-002 in NMIBC | |
$ | 6,848 | | |
$ | 4,898 | | |
$ | 12,686 | | |
$ | 8,455 | |
| TARA-002 in LMs | |
| 852 | | |
| 477 | | |
| 1,660 | | |
| 1,027 | |
| IV Choline Chloride | |
| 2,726 | | |
| 1,852 | | |
| 4,946 | | |
| 4,367 | |
| Other research and development | |
| 6,165 | | |
| 3,317 | | |
| 10,449 | | |
| 5,651 | |
| General and administrative expenses | |
| 5,349 | | |
| 5,139 | | |
| 10,466 | | |
| 9,474 | |
| Stock-based compensation expense | |
| 1,384 | | |
| 903 | | |
| 2,746 | | |
| 1,736 | |
| Income (loss) from operations | |
| (23,324 | ) | |
| (16,586 | ) | |
| (42,953 | ) | |
| (30,710 | ) |
| Other income (expense), net | |
| 1,656 | | |
| 1,626 | | |
| 3,503 | | |
| 3,836 | |
| Segment net income (loss) | |
| (21,668 | ) | |
| (14,960 | ) | |
| (39,450 | ) | |
| (26,874 | ) |
| Adjustments and reconciling items | |
| - | | |
| - | | |
| - | | |
| - | |
| Net income (loss) | |
$ | (21,668 | ) | |
$ | (14,960 | ) | |
$ | (39,450 | ) | |
$ | (26,874 | ) |
|